Upgrade to SI Premium - Free Trial

Pfizer (PFE), Astellas Pharma Inc. Reports Amendments to Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide

August 22, 2018 5:01 PM
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. today announced amendments to the protocols for two registrational Phase 3 trials ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

FDA Management Comments

Next Articles